Mukkunda Ravindra, Venkitaraman Ramachandran, Thway Khin, Min Toon, Fisher Cyril, Horwich Alan, Judson Ian
Urology Unit, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK.
Sarcoma. 2009;2009:504654. doi: 10.1155/2009/504654. Epub 2009 May 26.
Background. Ewing's sarcoma of extraskeletal origin is uncommon and that is of primary renal origin in adults are rare. There is no consensus on the optimal management of Ewing's tumors of renal origin. Methods. A retrospective review of the clinical features, treatment, and outcome of adult patients with primary renal extra-skeletal Ewing's sarcoma who were treated at the Royal Marsden hospital from January 1993-December 2007 is reported. Results. Seven adult patients with primary renal Ewing's sarcoma were identified. All four patients with nonmetastatic disease had radical nephrectomy and received adjuvant chemotherapy +/- radiotherapy. Two developed metastatic disease while on adjuvant chemotherapy, and one patient relapsed after 55 months. The three patients with metastatic disease at presentation did not have nephrectomy and were treated with chemotherapy. All three patients had disease progression with a dismal outcome. Only one patient in the whole group is alive and disease free. The median overall survival was 62.8 months, and the median disease-free survival in patients with nonmetastatic disease after combined modality treatment was 30.3 months. Conclusion. Primary adult renal Ewing's sarcoma is an aggressive tumor with a propensity for early metastasis. Radical nephrectomy with adjuvant combination chemotherapy produced the best results but the outlook remained poor with only one patient experiencing long disease-free survival.
背景。骨外尤文肉瘤并不常见,成人原发性肾源性尤文肉瘤则更为罕见。对于肾源性尤文肿瘤的最佳治疗方案尚无共识。方法。报告了对1993年1月至2007年12月在皇家马斯登医院接受治疗的成人原发性肾外尤文肉瘤患者的临床特征、治疗及预后的回顾性分析。结果。共确定了7例成人原发性肾尤文肉瘤患者。所有4例非转移性疾病患者均接受了根治性肾切除术,并接受辅助化疗和/或放疗。2例在辅助化疗期间发生转移性疾病,1例在55个月后复发。3例初诊时为转移性疾病的患者未接受肾切除术,而是接受了化疗。所有3例患者病情均进展,预后不佳。全组仅1例患者存活且无疾病。总体中位生存期为62.8个月,联合治疗后非转移性疾病患者的无病中位生存期为30.3个月。结论。成人原发性肾尤文肉瘤是一种侵袭性肿瘤,易于早期转移。根治性肾切除术联合辅助化疗效果最佳,但预后仍然不佳,仅有1例患者获得了长期无病生存。